Bill Crossman is an unlikely candidate to run a pharmaceutical firm.
The 71-year-old Connecticut businessman had spent decades growing a diverse collection of companies making everything from elevators to eco-friendly products. He had never run a drug company — and had little to no experience in the industry.
Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!
SUBSCRIBE TODAYWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
Hopefully the claims he makes turn out to be true in humans. If it does reach market physicians would likely still provide abusive drugs – look at the slow up take of abuse deterrent opioids (just get the non deterrent generic instead).